Deepinder Goyal shares a brief response to a tech commentator’s claim that people should not build healthcare startups in India. The exchange centers on Goyal’s approach and the broader debate about what it takes to succeed in healthcare entrepreneurship.

Across the coverage, outlets include context about a specific healthcare-related offering: a “Temple” launch that opens for pre-orders on November 1, priced at Rs 85,000. Both reports also note that doctors have questioned certain scientific claims connected to the product. While the headline framing focuses on the 12-word response and the criticism itself, the included details point to ongoing scrutiny of healthcare technologies and the evidence behind their claims. Neither source provides additional policy or regulatory developments beyond these points.